The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Insights into the real-world efficacy of luspatercept in patients with LR-MDS
In this video, Yazan Madanat, MD, UT Southwestern Medical Center, Dallas, TX, discusses the real-world efficacy of luspatercept in patients with lower-risk myelodysplastic syndromes (LR-MDS). When considering efficacy, a longer median duration of response was observed than in the MEDALIST trial (NCT02631070), despite the patient population differing substantially in terms of prior hypomethylating agent (HMA) and lenalidomide exposure. Additionally, escalating luspatercept doses appeared important, as half of the patients who had lost their initial response to treatment regained it with increased doses. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria: Taiho oncology, Stemline therapeutics, Morphosys, Sierra Oncology, Novartis, OncLive, MD Education, Rigel Pharmaceuticals, Blueprint Medicines; Consultancy: GERON, Blueprint Medicines.
